Forian Inc. reports 50% revenue growth for 2025, achieves Adjusted EBITDA targets, and receives acquisition proposal from CEO-led consortium. Life sciences dataForian Inc. reports 50% revenue growth for 2025, achieves Adjusted EBITDA targets, and receives acquisition proposal from CEO-led consortium. Life sciences data

Forian Reports Strong Revenue Growth Amid Strategic Investments and Potential Acquisition Talks

2026/03/28 04:00
3분 읽기
이 콘텐츠에 대한 의견이나 우려 사항이 있으시면 crypto.news@mexc.com으로 연락주시기 바랍니다

Forian Inc., a provider of data science driven information and analytics solutions, reported financial results for the fourth quarter and full year ended December 31, 2025, highlighting substantial revenue growth alongside strategic investments that impacted short-term profitability. The company’s full-year revenue increased by 50% to $30.3 million from $20.2 million in the prior year, while fourth-quarter revenue grew 37% to $8.0 million. This performance demonstrates the company’s expanding market presence in life sciences, healthcare, and financial services sectors.

Despite the revenue growth, Forian reported a net loss of $2.9 million for the full year, an improvement from the $3.8 million loss in 2024. The fourth quarter showed a net loss of $1.8 million compared to net income of $0.2 million in the same period last year. Adjusted EBITDA, a non-GAAP measure the company uses to evaluate performance, showed improvement for the full year at $0.8 million compared to $0.5 million in 2024, though it turned negative in the fourth quarter at $(0.2) million. Chief Executive Officer Max Wygod stated that the company demonstrated ‘disciplined cost management and strategic investment can go hand in hand’ during 2025.

The company’s financial position remained strong with cash, cash equivalents and marketable securities totaling $31.6 million at year-end. Forian highlighted several operational achievements including meeting its revenue guidance target through key contract renewals, achieving targeted Adjusted EBITDA margins, and strengthening its data platform through expanded contracting activity and new clinical data feeds. The company also noted growing pharmaceutical and biotech adoption of its offerings.

A significant corporate development emerged on August 25, 2025, when a consortium led by Forian’s Chief Executive Officer and Executive Chair submitted a non-binding proposal to acquire all outstanding shares not currently owned by the consortium. A Special Committee formed to evaluate this proposal remains in place and is in discussions with the consortium. The company cautioned that there can be no assurance that any transaction will result from these discussions. For more detailed financial information, investors can visit the company’s website at https://www.forian.com.

The company’s results reflect the challenges of balancing growth investments with profitability in the competitive data analytics sector. Forian’s expansion into new markets and strengthening of its data foundation position the company for future opportunities, though the potential acquisition talks add uncertainty to its corporate trajectory. The mixed financial metrics—strong revenue growth alongside net losses—illustrate the company’s transitional phase as it invests in platform development while managing operational costs.

Blockchain Registration, Verification & Enhancement provided by NewsRamp™

This news story relied on content distributed by NewMediaWire. Blockchain Registration, Verification & Enhancement provided by NewsRamp™. The source URL for this press release is Forian Reports Strong Revenue Growth Amid Strategic Investments and Potential Acquisition Talks.

The post Forian Reports Strong Revenue Growth Amid Strategic Investments and Potential Acquisition Talks appeared first on citybuzz.

면책 조항: 본 사이트에 재게시된 글들은 공개 플랫폼에서 가져온 것으로 정보 제공 목적으로만 제공됩니다. 이는 반드시 MEXC의 견해를 반영하는 것은 아닙니다. 모든 권리는 원저자에게 있습니다. 제3자의 권리를 침해하는 콘텐츠가 있다고 판단될 경우, crypto.news@mexc.com으로 연락하여 삭제 요청을 해주시기 바랍니다. MEXC는 콘텐츠의 정확성, 완전성 또는 시의적절성에 대해 어떠한 보증도 하지 않으며, 제공된 정보에 기반하여 취해진 어떠한 조치에 대해서도 책임을 지지 않습니다. 본 콘텐츠는 금융, 법률 또는 기타 전문적인 조언을 구성하지 않으며, MEXC의 추천이나 보증으로 간주되어서는 안 됩니다.